Gastro-oesophageal reflux disease: New therapeutic perspectives;Enfermedad por reflujo gastroesofágico: Nuevas perspectivas terapéuticas

Revista Espanola de Enfermedades Digestivas

Volumn 93, Issue 4, 2001, Pages 248-257

  Sobrino Faya, M ^a   Dominguez Munoz J E ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTACID AGENT; CIMETIDINE; CISAPRIDE; CLEBOPRIDE; COLESTYRAMINE; CYTOCHROME P450 3A4; DOMPERIDONE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; ROXATIDINE; SEROTONIN 1 RECEPTOR; SEROTONIN 4 RECEPTOR; SUCRALFATE;

ANTIREFLUX OPERATION; ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; DRUG EFFICACY; ENDOSCOPIC SURGERY; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMAN; LOWER ESOPHAGUS SPHINCTER PRESSURE; REVIEW;

GASTROESOPHAGEAL REFLUX; HUMANS;

EID: 0009734805     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Johnsson L, Adlouni W, Johnsson F, et al. Timing of reflux symptoms and esophageal acid exposure. Gullet 1992; 2 (2): 58-62.
2. Robertson DAF, Aldersley MA, Shepherd H, et al. Patterns of acid reflux in complicated esophagitis. Gut 1987; 28: 1484-8.
3. McDougall NI, Watson RGP, Collins JSA, et al. Maintenance therapy with cisapride after healing of erosive oesophagitis: a double-blind placebo-controlled trial. Aliment Pharmacol Ther 1997; 11 (3): 487-95.
4. Verhagen MA, Samson M, Maes B, et al. Effects of a new motilide, ABT-229, on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Aliment Pharmacol Ther 1997; 11 (6): 1077-86.
5. Van Herwaarden MA, Samson M, Van Nispen CH, et al. The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients. Aliment Pharmacol Ther 2000; 14 (4): 453-62.
6. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-12.
7. Thjodleifsson B, Dekkers CPM, Beker JA, et al. Rabeprazole sodium (E3810) once daily is similar to omeprazole 20 mg daily in the treatment of erosive or ulcerative GERD. Gastroenterology 1997; 112 (suppl): A312. Abstract.
8. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14 (7): 861-7.
9. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999; 44 (suppl 2).
10. Havelund T, Lind T, Wicklund I, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94 (7): 1782-9.
11. Zeitoun P, Rampal P, Barbier P, et al. Omeprazole (20 mg daily) compared to ranitidine (150 mg twice daily) in the treatment of esophagitis caused by reflux. Results of a double-blind randomized multicenter trial in France and Belgium. Gastroenterol Clin Biol 1989; 13 (5): 457-62.
12. Sandmark S, Carlsson R, Fausa O, et al. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 1988; 23 (5): 625-32.
13. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997; 112 (6): 1798-810.
14. Tytgat GN, Nicolai JJ, Reman FC. Efficacy of different doses of cimetidine in the treatment of reflux esophagitis. A review of three large, double-blind, controlled trials. Gastroenterology 1990; 99 (3): 629-34.
15. Johnson NJ, Boyd EJ, Mills JG, et al. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther 1989; 3 (3): 259-66.
16. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10 (2): 119-24.
17. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32 (10): 974-9.
18. Carlsson R, Galmiche JP, Dent J, et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11 (3): 473-82.
19. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. New Engl J Med 1995; 333 (17): 1106-10.
20. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10 (4): 529-39.
21. Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: Relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994; 107 (3): 747-54.
22. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115 (6): 1335-9.
23. Khoury RM, Katz PO, Hammond R, et al. Bedtime ranitidine does not eliminate the need for a second dose omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther 1999; 13 (5): 675-8.
24. Katsube T, Adachi K, Kawamura A, et al. Helicobacter pylori infection influences nocturnal acid breakthrough. Aliment Pharmacol Ther 2000; 14 (8): 1049-56.
25. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13 (7): 907-14.
26. Solcia E, Fiocca R, Havu N, et al. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992; 51 (suppl 1): 82-92.
27. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118 (4): 661-9.
28. Laws HL, Clements RH, Swillie CM. A randomized, prospective comparison of the Nissen fundoplication versus the Toupet fundoplication for gastroesophageal reflux disease. Ann Surg 1997; 225 (6): 647-53; discussion 654.
29. Heudebert GR, Marks R, Wilcox CM, et al. Choice of long-term strategy for the management of patientswith severe esophagitis: a cost utility analysis. Gastroenterology 1997; 112: 1078-86.
30. Kadirkamanathan SS, Evans DF, Gong F, et al. Antireflux operations at flexible endoscopy using endoluminal stitching techniques: an experimental study. Gastrointest Endosc 1996; 44 (2): 133-43.
31. Swain CP. Endoscopic suturing. Bailliere's Clin Gastroenterol 1999; 13 (1): 97-108.
32. Martínez-Serna T, Davis RE, Mason R, et al. Endoscopic valvuloplasty for GERD; Gastrointest Endosc 2000; 52 (5): 663-70.
33. Jaspersen D, Schwacha H, Schorr W, et al. Omeprazole in the treatment of patients with complicated gastro-oesophaseal reflux disease. J Gastroenterol Hepatol 1996; 11 (10): 900-2.
34. Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology 1994; 107 (5): 1312-8.
35. Silvis SE, Farahmand M, Johnson JA, et al. A randomized blinded comparison of omeprazole and ranitidine in the treatment of chronic esophageal stricture secondary to acid peptic esophagitis. Gastrointest Endosc 1996; 43 (3): 216-21.
36. Swarbrick ET, Gouh AL, Foster CS, et al. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. Eur J Gastoenterol Hepatol 1996; 8 (5): 431-8.
37. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 582-5.
38. Gore S, Healey CJ, Sutton R, et al. Regression of columnar-lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7: 623-8.
39. Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's oesophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44: 700-5.
40. Berenson MM, Johnson TD, Markowitz NR, et al. Restoration of squamous mucosa after ablation of Barrett's esophageal epitelium. Gastroenterology 1993; 104: 1686-91.
41. Van Laethem JL, Cremer M, Peny MO, et al. Eradication of Barrett's mucosa with argon plasma coagulation and acid supression: inmediate and mid term results. Gut 1998; 43: 747-51.
42. Stüeker D, Dopieralski A, Zindel C, et al. Argon plasma coagulation (APC) for ablation of Barrett epithelium/first clinical results in 21 patients. World Congresses of Gastroenterology, Vienna 1998; ExhB4150.
43. Schulz H, Miehlke S, Antos D, et al. Ablation of Barret's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc 2000; 51 (6): 659-63.
44. Brand B, Porthun M, von Schrenck T, et al. Endoscopic argon plasma coagulation of Barrett mucosa. Zentralbl Chir, 2000; 125 (5): 437-42.
45. Grade AJ, Shah IA, Medlin SM, et al. The efficacy and safety of argon plasma coagulation therapy in Barrett's esophagus. Gastrointest Endosc 1999; 50(1): 18-22.
46. Van Laethem JL, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelisation of Barrett's oesophagus. Gut 2000; 46 (4): 574-7.